HYDROXYCHLOROQUINE AND COVID-19: META-ANALYSIS OF 197 STUDIES (REFERENCES)
References for HYDROXYCHLOROQUINE AND COVID-19: META-ANALYSIS OF 197 STUDIES:
Abd-Elsalam et al., American Journal of Tropical Medicine and Hygiene, 10.4269/ajtmh.20-0873, Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study, https://www.ajtmh.org/content/journals/10.4269/ajtmh.20-0873.
Abdulrahman et al., medRxiv, doi:10.1101/2020.11.25.20234914, The efficacy and safety of hydroxychloroquine in COVID19 patients : a multicenter national retrospective cohort , https://www.medrxiv.org/content/10.1101/2020.11.25.20234914v1.
Abella et al., JAMA Internal Medicine, doi:doi:10.1001/jamainternmed.2020.6319, Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers, https://jamanetwork.com/journals/j..ternalmedicine/fullarticle/2771265.
Ader et al., medRxiv, doi:10.1101/2021.01.08.20248149 (news 10/6), Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial, https://www.medrxiv.org/content/10.1101/2021.01.08.20248149v1.
AFP, India backs hydroxychloroquine for virus prevention, https://www.msn.com/en-ph/news/wor..us-prevention/ar-BB14EloP?ocid=st2.
AfricaFeeds, Kenya approve the use of Chloroquine to treat COVID-19 patients, https://africafeeds.com/2020/04/01..oquine-to-treat-covid-19-patients/.
Africanews, Coronavirus patients on chloroquine heal faster - Senegalese medic, https://www.africanews.com/2020/04..uine-heal-faster-senegalese-medic/.
Afrik.com, Edouard Philippe emporté par le Covid, Didier Raoult, l’hydroxychloroquine et le… remdésivir, https://www.afrik.com/edouard-phil..ydroxychloroquine-et-le-remdesivir.
Águila-Gordo et al., Revista Española de Geriatría y Gerontología, doi:10.1016/j.regg.2020.09.006, Mortality and associated prognostic factors in elderly and very elderly hospitalized patients with respiratory disease COVID-19, https://www.sciencedirect.com/science/article/pii/S0211139X20301748.
Agusti et al., Enfermedades Infecciosas y Microbiología Clínica, doi:10.1016/j.eimc.2020.10.023, Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: prospective, non-randomized trial, https://www.sciencedirect.com/scie../article/abs/pii/S0213005X20304134.
Al Arabia, Bahrain among first countries to use Hydroxychloroquine to treat coronavirus, https://english.alarabiya.net/en/N..xychloroquine-to-treat-coronavirus.
Al-bab, Covid-19: Algeria and Morocco continue using chloroquine despite concerns, https://al-bab.com/blog/2020/05/co..using-chloroquine-despite-concerns.
Alamdari et al., Tohoku J. Exp. Med., 2020, 252, 73-84, doi:10.1620/tjem.252.73, Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran, https://www.jstage.jst.go.jp/artic..em/252/1/252_73/_article/-char/ja/.
Alberici et al., Kidney Int., 98:1, 20-26, July 1, 2020, doi:10.1016/j.kint.2020.04.030 (preprint 5/10), A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection, https://www.kidney-international.o..cle/S0085-2538(20)30508-1/fulltext.
Almazrou et al., Saudi Pharmaceutical Journal, doi:10.1016/j.jsps.2020.09.019, Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study, https://www.sciencedirect.com/science/article/pii/S1319016420302334.
Alqassieh et al., F1000Research, Preprint, Clinical characteristics and predictors of the duration of hospital stay in COVID-19 patients in Jordan, https://f1000research.com/articles/9-1439.
Altman, D., BMJ, doi:10.1136/bmj.d2304, How to obtain the P value from a confidence interval, https://www.bmj.com/content/343/bmj.d2304.
Altman (B) et al., BMJ, doi:10.1136/bmj.d2090, How to obtain the confidence interval from a P value, https://www.bmj.com/content/343/bmj.d2090.
An et al., medRxiv, doi:10.1101/2020.07.04.20146548, Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea, https://www.medrxiv.org/content/10.1101/2020.07.04.20146548v1.
Anadolu Agency, Nigeria goes on with hydroxychloroquine clinical trial, https://www.aa.com.tr/en/africa/ni..hloroquine-clinical-trials/1854814.
Anadolu Agency (B), Cuba: Early hydroxychloroquine potent against COVID-19, https://www.aa.com.tr/en/americas/..ne-potent-against-covid-19/1905650.
Anglemyer et al., Cochrane Database of Systematic Reviews 2014, Issue 4, doi:10.1002/14651858.MR000034.pub2, Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials, https://www.cochranelibrary.com/cd..0.1002/14651858.MR000034.pub2/full.
Annie et al., Pharmacotherapy, doi:10.1002/phar.2467, Hydroxychloroquine in hospitalized COVID‐19 patients: Real world experience assessing mortality, https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/phar.2467.
Aparisi et al., medRxiv, doi:10.1101/2020.10.06.20207092, Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19, https://www.medrxiv.org/content/10.1101/2020.10.06.20207092v1.
Archyde, China approves chloroquine (instead of hydroxychloroquine) against covid-19, https://www.archyde.com/china-appr..droxychloroquine-against-covid-19/.
Arleo et al., medRxiv, doi:10.1101/2020.10.26.20219154, Clinical Course and Outcomes of coronavirus disease 2019 (COVID-19) in Rheumatic Disease Patients on Immunosuppression: A case Cohort Study at a Single Center with a Significantly Diverse Population, https://www.medrxiv.org/content/10.1101/2020.10.26.20219154v1.
Arshad et al., Int. J. Infect. Dis., July 1 2020, doi:10.1016/j.ijid.2020.06.099, Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19, https://www.ijidonline.com/article/S1201-9712(20)30534-8/fulltext.
Ashinyo et al., Pan African Medical Journal, 37:1, doi:10.11604/pamj.supp.2020.37.1.25718, Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study, https://www.panafrican-med-journal.com/content/series/37/1/9/full/.
Ashraf et al., medRxiv doi:10.1101/2020.04.20.20072421.t, COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes, https://www.researchgate.net/publi..rom_exposure_to_treatment_outcomes.
Auld et al., Critical Care Medicine, doi:10.1097/ccm.0000000000004457, ICU and ventilator mortality among critically ill adults with COVID-19, https://journals.lww.com/ccmjourna..ality_Among_Critically_Ill.35.aspx.
Axfors et al., medRxiv, doi:10.1101/2020.09.16.20194571, Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials, https://www.medrxiv.org/content/10.1101/2020.09.16.20194571v1.
Ayerbe et al., Internal and Emergency Medicine, doi:0.1007/s11739-020-02505-x, The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients, https://link.springer.com/article/10.1007/s11739-020-02505-x.
Barbosa et al., Preprint, Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19: a quasi-randomized comparative study, https://www.sefq.es/_pdfs/NEJM_Hydroxychlorquine.pdf.
Barnabas et al., Annals of Internal Medicine, doi:10.7326/M20-6519, Hydroxychloroquine for Post-exposure Prophylaxis to Prevent Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Trial, https://www.acpjournals.org/doi/10.7326/M20-6519.
Barron's, Hydroxychloroquine: A Drug Dividing The World, https://www.barrons.com/news/hydro..rug-dividing-the-world-01591006809.
Barron's (B), Amid Global Controversy, Greece Moves Forward With Chloroquine, https://www.barrons.com/news/amid-..rward-with-chloroquine-01591781707.
BBC, Coronavirus: How Turkey took control of Covid-19 emergency, https://www.bbc.com/news/world-europe-52831017.
Behera et al., medRxiv, doi:10.1101/2020.10.29.20222661v1, Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study, https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1.
Belayneh, A., Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO Recommendation, https://www.dovepress.com/off-labe..eer-reviewed-fulltext-article-RRTM.
Berenguer et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.07.024, Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain, https://www.clinicalmicrobiologyan..cle/S1198-743X(20)30431-6/fulltext.
Bernabeu-Wittel et al., J. Gerontol. A Biol. Sci. Med. Sci., doi:10.1093/gerona/glaa192, Effectiveness of a On-Site Medicalization Program for Nursing Homes with COVID-19 Outbreaks, https://academic.oup.com/biomedger..doi/10.1093/gerona/glaa192/5879759.
Bernaola et al., medRxiv, doi:10.1101/2020.07.17.20155960, Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid, https://www.medrxiv.org/content/10.1101/2020.07.17.20155960v1.
Berry et al., SSRN, Berry, doi:10.2139/ssrn.3707327., Unfavorable Hydroxychloroquine COVID-19 Research Associated with Authors Having a History of Political Party Donations, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3707327.
Bhattacharya et al., medRxix, doi:10.1101/2020.06.09.20116806, Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers, https://www.medrxiv.org/content/10.1101/2020.06.09.20116806v1.
Bianet, Turkey begins distributing hydroxychloroquine to homes in capital city amid bed shortage, https://bianet.org/english/health/..-in-capital-city-amid-bed-shortage.
Bielza et al., Journal of the American Medical Directors Association, doi:10.1016/j.jamda.2020.12.003, Clinical characteristics, frailty and mortality of residents with COVID-19 in nursing homes of a region of Madrid, https://www.sciencedirect.com/science/article/pii/S1525861020310525.
Boari et al, Biosci. Rep., doi:10.1042/BSR20203455, Prognostic factors and predictors of outcome in patients with COVID-19 and related pneumonia: a retrospective cohort study, https://portlandpress.com/bioscire..cle/doi/10.1042/BSR20203455/226985.
Borba et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2020.8857, Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study), https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765499.
Boulware, D., Comments regarding paper rejection, https://twitter.com/boulware_dr/status/1311331372884205570.
Boulware (B) et al., NEJM, June 3 2020, doi:10.1056/NEJMoa2016638, A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19, https://www.nejm.org/doi/full/10.1056/NEJMoa2016638.
Bousquet et al., Aging, 12:12, 11306-11313, doi:10.18632/aging.103583, ADL-dependency, D-Dimers, LDH and absence of anticoagulation are independently associated with one-month mortality in older inpatients with Covid-19, https://www.aging-us.com/article/103583/text.
Budhiraja et al., medRxiv, doi:10.1101/2020.11.16.20232223, Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience, https://www.medrxiv.org/content/10.1101/2020.11.16.20232223v1.
Cadegiani et al., medRxiv, doi:10.1101/2020.10.31.20223883, Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients, https://www.medrxiv.org/content/10.1101/2020.10.31.20223883v1.
Cangiano et al., Aging, doi:10.18632/aging.202307, Mortality in an Italian nursing home during COVID-19 pandemic: correlation with gender, age, ADL, vitamin D supplementation, and limitations of the diagnostic tests, https://www.aging-us.com/article/202307/text.
Capsoni et al., Research Square, doi:10.21203/rs.3.rs-113418/v1, CPAP Treatment In COVID-19 Patients: A Retrospective Observational Study In The Emergency Department, https://www.researchsquare.com/article/rs-113418/v1.
Cassione et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217717, COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine, https://ard.bmj.com/content/early/..05/23/annrheumdis-2020-217717.info.
Catteau et al., Int. J. Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106144, Low-dose Hydroxychloroquine Therapy and Mortality in Hospitalized Patients with COVID-19: A Nationwide Observational Study of 8075 Participants, https://www.sciencedirect.com/scie../article/abs/pii/S0924857920303423.
Cavalcanti et al., NEJM, July 23, 2020, doi:10.1056/NEJMoa2019014, Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19, https://www.nejm.org/doi/full/10.1056/NEJMoa2019014.
CBS News, Turkey claims success treating virus with drug touted by Trump, https://www.msn.com/en-au/news/wor..h-drug-touted-by-trump/ar-BB13oMXS.
Challenge, Coronavirus : ce que le Maroc a réussi, https://www.challenge.ma/coronavirus-ce-que-le-maroc-a-reussi-144484/.
Chari et al., Blood, doi:10.1182/blood.2020008150, Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set, https://www.sciencedirect.com/science/article/pii/S0006497120839044.
Chatterjee et al., Indian J. Med. Res., June 20, 2020, doi:10.4103/ijmr.IJMR_2234_20, Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19, https://www.ijmr.org.in/article.as..ge=459;epage=467;aulast=Chatterjee.
Chen et al., medRxiv, doi:10.1101/2020.06.19.20136093, Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study, https://www.medrxiv.org/content/10.1101/2020.06.19.20136093v1.
Chen (B) et al., PLOS ONE, doi:10.1371/journal.pone.0242763, A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19), https://journals.plos.org/plosone/..le?id=10.1371/journal.pone.0242763.
Chen (C) et al., PLOS ONE, doi:10.1371/journal.pone.0242763, A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19), https://journals.plos.org/plosone/..le?id=10.1371/journal.pone.0242763.
Chen (D) et al., medRxiv doi:10.1101/2020.03.22.20040758, Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v3.
Chen (E) et al., J. Zhejiang University (Med Sci), doi:10.3785/j.issn.1008-9292.2020.03.03, A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19), http://www.zjujournals.com/med/EN/..cleFile.do?attachType=PDF&id=41137.
Choi et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.10.062, Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study, https://www.sciencedirect.com/science/article/pii/S1201971220322669.
Coll et al., American Journal of Transplantation, doi:10.1111/ajt.16369, Covid‐19 in transplant recipients: the spanish experience, https://onlinelibrary.wiley.com/doi/abs/10.1111/ajt.16369.
Concato et al., NEJM, 342:1887-1892, doi:10.1056/NEJM200006223422507, https://www.nejm.org/doi/full/10.1056/nejm200006223422507.
Cordtz et al., Rheumatology, doi:10.1093/rheumatology/keaa897, Incidence and severeness of COVID-19 hospitalisation in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark, https://academic.oup.com/rheumatol...1093/rheumatology/keaa897/6053804.
Cravedi et al., American Journal of Transplantation, doi:10.1111/ajt.16185, COVID‐19 and kidney transplantation: Results from the TANGO International Transplant Consortium, https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.16185.
D'Arminio Monforte et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2020.07.056, Effectiveness of Hydroxychloroquine in COVID-19 disease: A done and dusted situation?, https://www.ijidonline.com/article/S1201-9712(20)30600-7/fulltext.
Davido et al., Int. J. Antimicrobial Agents, 2020, doi:10.1016/j.ijantimicag.2020.106129, Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time, https://www.sciencedirect.com/science/article/pii/S0924857920303125.
de la Iglesia et al., medRxiv, doi:10.1101/2020.08.31.20185314, Hydroxicloroquine for pre-exposure prophyylaxis for SARS-CoV-2, https://www.medrxiv.org/content/10.1101/2020.08.31.20185314v1.
Deaton et al., Social Science & Medicine, 210, doi:10.1016/j.socscimed.2017.12.005, Understanding and misunderstanding randomized controlled trials, https://www.sciencedirect.com/science/article/pii/S0277953617307359.
Derwand et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106214 (preprint 7/3), COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study, https://www.sciencedirect.com/science/article/pii/S0924857920304258.
Desbois et al., Research Square, doi:10.21203/rs.3.rs-41653/v1, Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis, https://www.researchsquare.com/article/rs-41653/v1.
Dhibar et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106224, Post Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the Prevention of COVID-19, a Myth or a Reality? The PEP-CQ Study, https://www.sciencedirect.com/science/article/pii/S0924857920304350.
Di Castelnuovo et al., European J. Internal Medicine, doi:10.1016/j.ejim.2020.08.019, Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study, https://www.sciencedirect.com/scie../article/abs/pii/S0953620520303356.
Dr. Goldin, Summary of HCQ usage in India from an MD in India, https://www.facebook.com/groups/hy..oquine/permalink/2367454293560817/.
Dubee et al., medRxiv, doi:10.1101/2020.10.19.20214940, A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19, https://www.medrxiv.org/content/10.1101/2020.10.19.20214940v1.
Dubernet et al., J. Global Antimicrobial Resistance, doi:10.1016/j.jgar.2020.08.001, A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: results of a retrospective observational study in the French overseas department of Reunion Island, https://www.sciencedirect.com/science/article/pii/S221371652030206X.
Efecto Cocuyo, Venezuela empieza a usar la cloroquina para tratar COVID-19, anuncia Jorge Rodríguez, https://efectococuyo.com/coronavir..-covid-19-anuncia-jorge-rodriguez/.
Esper et al., Prevent Senior Institute, São Paulo, Brazil, Empirical treatment with hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up by telemedicine, https://www.dropbox.com/s/5qm58cd4..20journal%20manuscript%20final.pdf.
Expats.cz, Czech Health Ministry permits temporary use of hydroxychloroquine to treat COVID-19, https://news.expats.cz/weekly-czec..ne-in-hospitals-to-treat-covid-19/.
Face 2 Face Africa, Djibouti, others warned about chloroquine despite big COVID-19 recoveries, https://face2faceafrica.com/articl..ne-despite-big-covid-19-recoveries.
Faíco-Filho et al., Braz J Microbiol, doi:10.1007/s42770-020-00395-x (preprint 6/21), No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19, https://link.springer.com/article/10.1007/s42770-020-00395-x.
Falcone et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa563, Role of low-molecular weight heparin in hospitalized patients with SARS-CoV-2 pneumonia: a prospective observational study, https://academic.oup.com/ofid/adva..e/doi/10.1093/ofid/ofaa563/5992463.
Ferreira et al., J. Medical Virology, July 9, 2020, doi:10.1002/jmv.26286 (preprint 6/29), Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection, https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26286.
Ferri at al., Clinical Rheumatology, doi:0.1007/s10067-020-05334-7, COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series, https://link.springer.com/article/10.1007/s10067-020-05334-7.
Filipova et al., Health Science Journal, Is there a Correlation between Changes in Hydroxychloroquine Use and Mortality Rates from COVID-19?, https://www.hsj.gr/medicine/is-the..nd-mortalityrates-from-covid19.pdf.
Fonseca et al., Travel Medicine and Infectious Disease, doi:10.1016/j.tmaid.2020.101906, Risk of Hospitalization for Covid-19 Outpatients Treated with Various Drug Regimens in Brazil: Comparative Analysis, https://www.sciencedirect.com/scie../article/abs/pii/S1477893920304026.
Fontana et al., Clinical Kidney Journal, 13:3, 334–339, doi:10.1093/ckj/sfaa084, SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience, https://academic.oup.com/ckj/article/13/3/334/5860798.
France 24, Covid-19: In Cameroon, chloroquine therapy hailed by French expert becomes state protocol, https://www.france24.com/en/202005..ench-expert-becomes-state-protocol.
France 24 (B), Covid-19 : au Cameroun, la méthode Raoult érigée en protocole d'État, https://www.france24.com/fr/202005..ig%C3%A9e-en-protocole-d-%C3%A9tat.
Franceinfo, Ces pays africains qui ont décidé de continuer à soigner le Covid-19 avec l'hydroxychloroquine, https://www.francetvinfo.fr/monde/..-l-hydroxychloroquine_3983239.html.
Fried et al., Clinical Infectious Disease, doi:10.1093/cid/ciaa1268, Patient Characteristics and Outcomes of 11,721 Patients with COVID19 Hospitalized Across the United States, https://academic.oup.com/cid/advan..e/doi/10.1093/cid/ciaa1268/5898276.
Frontera et al., Research Square, doi:10.21203/rs.3.rs-94509/v1, Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study, https://www.researchsquare.com/article/rs-94509/v1.
Garcia-Albeniz et al., medRxiv, doi:10.1101/2020.09.29.20203869, Brief communication: A meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19, https://www.medrxiv.org/content/10.1101/2020.09.29.20203869v2.
Gautret et al., Int. J. of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.105949 (preprint 3/17), Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, https://www.sciencedirect.com/scie../article/abs/pii/S0924857920300996.
Geleris et al., NEJM, May 7, 2020, doi:10.1056/NEJMoa2012410, Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, https://www.nejm.org/doi/full/10.1056/NEJMoa2012410.
Gendebien et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-218244, Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments, https://ard.bmj.com/content/early/2020/06/25/annrheumdis-2020-218244.
Gendelman et al., Autoimmunity Reviews, 19:7, July 2020, doi:10.1016/j.autrev.2020.102566, Continuous Hydroxychloroquine or Colchicine Therapy Does Not Prevent Infection With SARS-CoV-2: Insights From a Large Healthcare Database Analysis, https://www.sciencedirect.com/science/article/pii/S1568997220301282.
Gentry et al., Lancet Rheumatology, doi:10.1016/S2665-9913(20)30305-2, Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study, https://www.thelancet.com/journals../PIIS2665-9913(20)30305-2/fulltext.
Gianfrancesco et al., Annals of the Rheumatic Diseases, 79:7, 859-866, doi:10.1136/annrheumdis-2020-217871, Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry, https://europepmc.org/article/med/32471903.
Global Times, Chinese medical expert decorated by Djibouti for COVID-19 prevention, https://www.globaltimes.cn/content/1189839.shtml.
Goenka et al., SSRN, doi:10.2139/ssrn.3689618, Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3689618.
Goldman et al., NEJM, doi:10.1056/NEJMoa2015301, Remdesivir for 5 or 10 Days in Patients with Severe Covid-19, https://www.nejm.org/doi/10.1056/NEJMoa2015301.
Gönenli et al., Research Square, doi:0.21203/rs.3.rs-107937/v1, Prophylactic use of Hydroxychloroquine among Physicians working in Pandemic Hospitals, https://www.researchsquare.com/article/rs-107937/v1.
Gonzalez et al., medRxiv, doi:10.1101/2020.08.18.20172874, The Prognostic Value of Eosinophil Recovery in COVID-19: A Multicentre, Retrospective Cohort Study on Patients Hospitalised in Spanish Hospitals, https://www.medrxiv.org/content/10.1101/2020.08.18.20172874v1.
Government of China, 关于印发新型冠状病毒肺炎诊疗方案(试行第八版)的通知, http://www.nhc.gov.cn/yzygj/s7653p..df12bd4b46e5bd28ca7f9a7f5e5a.shtml.
Government of India, The caregiver and all close contacts of such cases should take HCQ prophylaxis, https://www.mohfw.gov.in/pdf/RevisedHomeIsolationGuidelines.pdf.
Government of Venezuela, THERAPEUTIC MANAGEMENT GUIDE FOR COVID-19 PATIENTS AND CONTACTS, http://www.mpps.gob.ve/index.php/sistemas/descargas.
Grau-Pujol et al., Research Square, doi:10.21203/rs.3.rs-72132/v1, Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial, https://www.researchsquare.com/article/rs-72132/v1.
Guérin et al., Asian J. Medicine and Health, July 15, 2020, doi:10.9734/ajmah/2020/v18i730224 (preprint 5/31), Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19, https://www.journalajmah.com/index.php/AJMAH/article/view/30224.
Guglielmetti et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2020.11.012, Severe COVID-19 pneumonia in Piacenza, Italy – a cohort study of the first pandemic wave, https://www.sciencedirect.com/science/article/pii/S1876034120307516.
Guisado-Vasco, Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort), https://www.sciencedirect.com/science/article/pii/S2589537020303357.
Guisado-Vasco (B), Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort), https://www.sciencedirect.com/science/article/pii/S2589537020303357.
GulfInsider, Coronavirus: Bahrain’s Therapeutic Medication Proved Effective, https://www.gulf-insider.com/coron..eutic-medication-proved-effective/.
Güner et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2020.12.017, Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir, and Hydroxychloroquine plus Favipiravir, https://www.sciencedirect.com/science/article/pii/S1876034120307735.
Gupta et al., JAMA Intern. Med., doi:10.1001/jamainternmed.2020.3596, Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US, https://jamanetwork.com/journals/j..ternalmedicine/fullarticle/2768602.
Heberto et al., IJC Heart & Vasculature, doi:10.1016/j.ijcha.2020.100638, Implications of myocardial injury in Mexican hospitalized patients with coronavirus disease 2019 (COVID-19), https://www.sciencedirect.com/science/article/pii/S2352906720303365.
Heras et al., European Geriatric Medicine, doi:10.1007/s41999-020-00432-w (preprint 9/2), COVID-19 mortality risk factors in older people in a long-term care center, https://link.springer.com/article/10.1007/s41999-020-00432-w.
Hong et al., Infect. Chemother., 2020, doi:10.3947/ic.2020.52.e43, Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication, https://icjournal.org/DOIx.php?id=10.3947/ic.2020.52.3.396.
Huang et al., Annals of the Rheumatic Diseases 2020:79, 1163-1169, doi:10.1136/annrheumdis-2020-217425, Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study, https://ard.bmj.com/content/79/9/1163.
Huang (B) et al., National Science Review, nwaa113, doi:10.1093/nsr/nwaa113, Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19, https://academic.oup.com/nsr/advan..le/doi/10.1093/nsr/nwaa113/5848167.
Huang (C) et al., National Science Review, nwaa113, doi:10.1093/nsr/nwaa113, Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19, https://academic.oup.com/nsr/advan..le/doi/10.1093/nsr/nwaa113/5848167.
Huang (D) et al., Journal of Molecular Cell Biology, Volume 12, Issue 4, April 2020, 322–325, doi:10.1093/jmcb/mjaa014, Treating COVID-19 with Chloroquine, https://academic.oup.com/jmcb/article/12/4/322/5814655.
Huh et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.12.041, Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea, https://www.sciencedirect.com/science/article/pii/S1201971220325650.
Huh (B) et al., medRxiv, doi:10.1101/2020.05.04.20089904, Association of previous medications with the risk of COVID-19: a nationwide claims-based study from South Korea, https://www.medrxiv.org/content/10.1101/2020.05.04.20089904v2.
IHU Marseille, Meta-analysis on chloroquine derivatives and COVID-19 mortality, https://www.mediterranee-infection..9-mortality-october20-2020-update/.
Ip et al., BMC Infectious Diseases, doi:10.1186/s12879-021-05773-w (preprint 8/25), Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study, https://bmcinfectdis.biomedcentral..rticles/10.1186/s12879-021-05773-w.
Ip (B) et al., PLOS ONE, doi:10.1371/journal.pone.0237693, Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study, https://journals.plos.org/plosone/..le?id=10.1371/journal.pone.0237693.
Izoulet M., SSRN, doi:10.2139/ssrn.3575899, Countries which Primarily Use Antimalarial Drugs As COVID-19 Treatment See Slower Dynamic of Daily Deaths, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3575899.
Jung et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.12.003, Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: A population-based cohort study, https://www.sciencedirect.com/science/article/pii/S1198743X20307527.
Kalligeros et al., Journal of Global Antimicrobial Resistance, doi:10.1016/j.jgar.2020.07.018, Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study, https://www.sciencedirect.com/science/article/pii/S2213716520301934.
Kamran et al., medRxiv, doi:10.1101/2020.07.30.20165365, Clearing the fog: Is HCQ effective in reducing COVID-19 progression: A randomized controlled trial, https://www.medrxiv.org/content/10.1101/2020.07.30.20165365v1.
Kelly et al., British Journal of Clinical Pharmacology, doi:10.1111/bcp.14482, Clinical outcomes and adverse events in patients hospitalised with COVID‐19, treated with off‐label hydroxychloroquine and azithromycin, https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.14482.
Khurana et al., medRxiv, doi:10.1101/2020.07.21.20159301, Prevalence and clinical correlates of COVID-19 outbreak among healthcare workers in a tertiary level hospital, https://www.medrxiv.org/content/10.1101/2020.07.21.20159301v1.
Kim et al., medRxiv, doi:10.1101/2020.05.13.20094193, Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea, https://www.medrxiv.org/content/10..20.05.13.20094193v1?versioned=true.
Kirenga et al., BMJ Open Respiratory Research, doi:10.1136/bmjresp-2020-000646, Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda, https://bmjopenrespres.bmj.com/content/7/1/e000646.
Komissarov et al., medRxiv, doi:10.1101/2020.06.30.20143289, Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of COVID-19, https://www.medrxiv.org/content/10.1101/2020.06.30.20143289v1.
Konig et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217690, Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19, https://ard.bmj.com/content/early/2020/05/20/annrheumdis-2020-217690.
Kuderer et al., Lancet, June 20, 2020, doi:10.1016/S0140-6736(20)31187-9 (preprint 5/28), Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study, https://www.thelancet.com/journals../PIIS0140-6736(20)31187-9/fulltext.
Ladapo et al., medRxiv, doi:10.1101/2020.09.30.20204693, Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis, https://www.medrxiv.org/content/10.1101/2020.09.30.20204693v1.
Lagier et al., Travel Med. Infect. Dis. 101791, Jun 25, 2020, doi:10.1016/j.tmaid.2020.101791, Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis, https://www.sciencedirect.com/science/article/pii/S1477893920302817.
Lambermont et al., Critical Care Explorations, doi:10.1097/CCE.0000000000000305, Predictors of Mortality and Effect of Drug Therapies in Mechanically Ventilated Patients With Coronavirus Disease 2019: A Multicenter Cohort Study, https://journals.lww.com/ccejourna..rtality_and_Effect_of_Drug.10.aspx.
Lammers et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2020.09.1460, Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients, https://www.sciencedirect.com/science/article/pii/S1201971220321755.
Lano et al., Clinical Kidney Journal, 13:5, October 2020, 878–888, doi:10.1093/ckj/sfaa199, Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort, https://academic.oup.com/ckj/article/13/5/878/5934808.
Laplana et al., PLOS ONE, doi:10.1371/journal.pone.0243598, Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients, https://journals.plos.org/plosone/..le?id=10.1371/journal.pone.0243598.
Lauriola et al., Clinical and Translational Science, doi:10.1111/cts.12860, Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID‐19 patients, https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1111/cts.12860.
Le Nouvel Afrik, Covid-19 : pourquoi les Marocains décèdent plus en Europe qu’au Maroc, https://www.afrik.com/covid-19-pou..ecedent-plus-en-europe-qu-au-maroc.
Lecronier et al., Critical Care, 24:418, 2020, doi:10.1186/s13054-020-03117-9, Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis, https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-03117-9.
Lee et al., Arch Intern Med., 2011, 171:1, 18-22, doi:10.1001/archinternmed.2010.482, Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines, https://jamanetwork.com/journals/j..nternalmedicine/fullarticle/226373.
Li et al., Science China Life Sciences, doi:10.1007/s11427-020-1871-4, Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19, https://link.springer.com/article/10.1007/s11427-020-1871-4.
Li (B) et al., Research Square, doi:10.21203/rs.3.rs-119202/v1, Treatment of COVID-19 patients with hydroxychloroquine or chloroquine: A retrospective analysis, https://www.researchsquare.com/article/rs-119202/v1.
LifeSiteNews, Doctors insist this cheap, safe drug is “key to preventing huge loss of life” from Wuhan virus, https://www.lifesitenews.com/news/..huge-loss-of-life-from-covid-virus.
López et al., Annals of Pediatrics, doi:10.1016/j.anpedi.2020.10.017 , Telemedicine follow-ups for COVID-19: experience in a tertiary hospital, https://www.sciencedirect.com/science/article/pii/S1695403320304768.
Luo et al., Annals of Oncology, 31:10, 1386-1396, doi:10.1016/j.annonc.2020.06.007, COVID-19 in patients with lung cancer, https://www.annalsofoncology.org/a..cle/S0923-7534(20)39894-X/fulltext.
Ly et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106219 (preprint 8/21), Pattern of SARS-CoV-2 infection among dependant elderly residents living in retirement homes in Marseille, France, March-June 2020, https://www.sciencedirect.com/scie../article/abs/pii/S0924857920304301.
Lyngbakken et al., Nature Communications, doi:10.1038/s41467-020-19056-6, A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics, https://www.nature.com/articles/s41467-020-19056-6.
Macias et al., medRxiv, 10.1101/2020.05.16.20104141, Similar incidence of Coronavirus Disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy, https://www.medrxiv.org/content/10.1101/2020.05.16.20104141v1.
Magagnoli et al., Med (2020), doi:10.1016/j.medj.2020.06.001 (preprint 4/21), Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19, https://www.sciencedirect.com/science/article/pii/S2666634020300064.
Mahévas et al., BMJ 2020, 369, doi: https://doi.org/10.1136/bmj.m1844, Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data, https://www.bmj.com/content/369/bmj.m1844.
Maldonado et al., Nefrología, doi:10.1016/j.nefro.2020.09.002, COVID-19 incidence and outcomes in a home dialysis unit in Madrid (Spain) at the height of the pandemic, https://www.sciencedirect.com/science/article/pii/S0211699520301661.
Mallat et al., Medicine (Baltimore), doi:10.1097/MD.0000000000023720 (preprint 5/2), Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study, https://journals.lww.com/md-journa..sociated_with_slower_viral.34.aspx.
Martinez-Lopez et al., Blood Cancer Journal, doi:10.1038/s41408-020-00372-5, Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality, https://www.nature.com/articles/s41408-020-00372-5.
Matangila et al., PLOS ONE, doi:10.1371/journal.pone.0244272, Clinical characteristics of COVID-19 patients hospitalized at Clinique Ngaliema, a public hospital in Kinshasa, in the Democratic Republic of Congo: A retrospective cohort study, https://journals.plos.org/plosone/..le?id=10.1371/journal.pone.0244272.
Mathai et al., J. Marine Medical Society, doi:10.4103/jmms.jmms_115_20, Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 in health-care workers: A single-center experience, https://www.marinemedicalsociety.in/preprintarticle.asp?id=300159.
McGrail et al., medRxiv, doi:10.1101/2020.07.17.20156521, COVID-19 Case Series at UnityPoint Health St. Luke’s Hospital in Cedar Rapids, IA, https://www.medrxiv.org/content/10.1101/2020.07.17.20156521v1.
McLean et al., Open Forum Infect. Dis. September 2015, 2:3, doi:10.1093/ofid/ofv100, Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525010/.
Medical World Nigeria, Chloroquine potent for COVID-19 prevention, says NAFDAC, https://medicalworldnigeria.com/po..9-Prevention-Says-NAFDAC?pid=45479.
Medical Xpress, Senegal says hydroxychloroquine virus treatment is promising, https://medicalxpress.com/news/202..xychloroquine-virus-treatment.html.
Medical Xpress (B), Amid global controversy, Greece moves forward with chloroquine, https://medicalxpress.com/news/202..ontroversy-greece-chloroquine.html.
Membrillo de Novales et al., Preprints 2020, 2020050057, doi:10.20944/preprints202005.0057.v1, Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study, https://www.preprints.org/manuscript/202005.0057.
Meneguesso, A., Médica defende tratamento precoce da Covid-19, https://www.youtube.com/watch?v=X5FCrIm_19U.
Middle East Eye, Coronavirus: Turkey says hydroxychloroquine dramatically reduces pneumonia cases, https://www.middleeasteye.net/news..roquine-malaria-treatment-progress.
Mikami et al., J. Gen. Intern. Med., doi:10.1007/s11606-020-05983-z, Risk Factors for Mortality in Patients with COVID-19 in New York City, https://link.springer.com/article/10.1007/s11606-020-05983-z.
Ministerstva Zdravotnictví, Rozhodnutí o dočasném povolení neregistrovaného humánního léčivého přípravku HYDROXYCHLOROQUINE SULFATE TABLETS, https://www.mzcr.cz/rozhodnuti-o-d..ydroxychloroquine-sulfate-tablets/.
Ministry of Health of Ukraine, ПРОТОКОЛ «НАДАННЯ МЕДИЧНОЇ ДОПОМОГИ ДЛЯ ЛІКУВАННЯ КОРОНАВІРУСНОЇ ХВОРОБИ (COVID-19)» , https://www.dec.gov.ua/wp-content/..04/2020_762_protokol_covid19-f.pdf.
Ministry of Health of Ukraine (B), «НАДАННЯ МЕДИЧНОЇ ДОПОМОГИ ДЛЯ ЛІКУВАННЯ КОРОНАВІРУСНОЇ ХВОРОБИ (COVID-19), https://moz.gov.ua/uploads/5/26129-dn_2106_17_09_2020_dod_1.pdf.
Mitchell et al., SSRN, doi:10.2139/ssrn.3586954, Markedly Lower Rates of Coronavirus Infection and Fatality in Malaria-Endemic Regions – A Clue As to Treatment?, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3586954.
Mitjà et al., Clinical Infectious Diseases, ciaa1009, doi:10.1093/cid/ciaa1009, Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial, https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa1009/5872589.
Mitjà (B) et al., NEJM, doi:10.1056/NEJMoa2021801 (preprint 7/26), A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease, https://www.nejm.org/doi/full/10.1056/NEJMoa2021801.
Modrák et al., medRxiv, doi:10.1101/2020.12.03.20239863, Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis, https://www.medrxiv.org/content/10.1101/2020.12.03.20239863v1.
Morocco World News, Moroccan Scientist: Morocco’s Chloroquine Success Reveals European Failures, https://www.moroccoworldnews.com/2..success-reveals-european-failures/.
Mosaique Guinee, Traitement des malades de covid19 en Guinée: « nous continuons avec l’hydroxychloroquine » (ANSS), https://mosaiqueguinee.com/traitem..ons-avec-lhydroxychloroquine-anss/.
Nachega et al., The American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.20-1240, Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo, https://www.ajtmh.org/content/journals/10.4269/ajtmh.20-1240.
Ñamendys-Silva et al., Heart & Lung, doi:10.1016/j.hrtlng.2020.10.013, Outcomes of patients with COVID-19 in the Intensive Care Unit in Mexico: A multicenter observational study, https://www.sciencedirect.com/science/article/pii/S014795632030412X.
Naseem et al., medRxiv, doi:10.1101/2020.12.13.20247254, Predicting mortality in SARS-COV-2 (COVID-19) positive patients in the inpatient setting using a Novel Deep Neural Network, https://www.medrxiv.org/content/10.1101/2020.12.13.20247254v1.
Nichol et al., Injury, 2010, doi: 10.1016/j.injury.2010.03.033, Challenging issues in randomised controlled trials, https://www.injuryjournal.com/article/S0020-1383(10)00233-0/fulltext.
Nigeria News World, COVID-19: Jigawa govt reveals secret behind mass recovery of patients, https://nigerianewsworld.com/news/..-behind-mass-recovery-of-patients/.
NPR News, Senegal pledges a bed for every coronavirus patient, https://wfuv.org/content/senegal-p..t-%E2%80%94-and-their-contacts-too.
Núñez-Gil et al., Intern. Emerg. Med., doi:10.1007/s11739-020-02543-5, Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649104/.
Omrani et al., EClinicalMedicine, doi:10.1016/j.eclinm.2020.100645, Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19, https://www.sciencedirect.com/science/article/pii/S2589537020303898.
Oneindia, No COVID-19 death in Manipur, Mizoram, Nagaland, Sikkim so far: Govt, https://www.oneindia.com/india/no-..o-far-health-ministry-3111048.html.
Orioli et al., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2020.12.020, Clinical characteristics and short-term prognosis of in-patients with diabetes and COVID-19: A retrospective study from an academic center in Belgium, https://www.sciencedirect.com/science/article/pii/S1871402120305154.
Ozturk et al., Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfaa271, Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey, https://academic.oup.com/ndt/article/35/12/2083/6020341.
Paccoud et al., Clinical Infectious Diseases, doi:10.1093/cid/ciaa791, Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital, https://academic.oup.com/cid/article/doi/10.1093/cid/ciaa791/5859555.
Pan African Medical Journal, Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study, https://www.panafrican-med-journal.com/content/series/37/1/9/full/.
Parola et al., COVID-19 in Africa: What else?, https://www.mediterranee-infection..oads/2020/09/COVIDAfricaJOUMII.pdf.
Peng et al., Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfaa288, Early versus late acute kidney injury among patients with COVID-19—a multicenter study from Wuhan, China , https://academic.oup.com/ndt/article/35/12/2095/6020340.
Peters et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2020.10.004 (preprint 8/15), Outcomes of Persons With COVID-19 in Hospitals With and Without Standard Treatment With (Hydroxy)chloroquine, https://www.clinicalmicrobiologyan..cle/S1198-743X(20)30615-7/fulltext.
Pilot News, Chloroquine Can Treat Coronavirus at Early Stage – NAFDAC DG, https://www.westafricanpilotnews.c..onavirus-at-early-stage-nafdac-dg/.
Pinato et al., Cancer Discovery, doi:10.1158/2159-8290.CD-20-0773, Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients, https://cancerdiscovery.aacrjourna..ly/2020/08/18/2159-8290.CD-20-0773.
PledgeTimes, Russian Ministry of Health has updated recommendations for the treatment of COVID-19, https://pledgetimes.com/russian-mi..ons-for-the-treatment-of-covid-19/.
Pleno.News, Cuba stands out in combating Covid with hydroxychloroquine, https://pleno.news/saude/coronavir..a-covid-com-hidroxicloroquina.html.
Polat et al., Medical Journal of Bakirkoy, 16:3, 280-6, doi:10.5222/BMJ.2020.50469, Hydroxychloroquine Use on Healthcare Workers Exposed to COVID-19 -A Pandemic Hospital Experience, https://www.bakirkoytip.org/jvi.as..oytip&plng=eng&un=BMJ-50469&look4=.
Prodromos et al., New Microbes and New Infections, doi:10.1016/j.nmni.2020.100776, Hydroxychloroquine is effective, and consistently so used early, for Covid-19: A systematic review, https://www.sciencedirect.com/science/article/pii/S2052297520301281.
Psevdos et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa439.721, Corona Virus Disease-19 (COVID-19) in a Veterans Affairs Hospital at Suffolk County, Long Island, New York, https://academic.oup.com/ofid/article/7/Supplement_1/S330/6057008.
Q Costa Rica, Hydroxychloroquine: The Drug Costa Rica Uses Successfully To Fight Covid-19, https://qcostarica.com/hydroxychlo..es-successfully-to-fight-covid-19/.
Qin et al., Thrombosis Research, doi:10.1016/j.thromres.2020.11.020, Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era, https://www.sciencedirect.com/science/article/pii/S0049384820306277.
Rajasingham et al., medRxiv, doi:10.1101/2020.09.18.20197327, Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial, https://academic.oup.com/cid/advan..e/doi/10.1093/cid/ciaa1571/5929230.
Rangel et al., Journal of the American Academy of Dermatology, doi:10.1016/j.jaad.2020.10.098, Chronic Hydroxychloroquine Therapy and COVID-19 Outcomes: A Retrospective Case-Control Analysis, https://www.sciencedirect.com/science/article/pii/S0190962221001109.
Rathi et al. Lancet Infect. Dis. doi:10.1016/S1473-3099(20)30313-3, Hydroxychloroquine prophylaxis for COVID-19 contacts in India, https://www.thelancet.com/journals../PIIS1473-3099(20)30313-3/fulltext.
RECOVERY Collaborative Group, NEJM, doi:10.1056/NEJMoa2022926 (press release 6/5), Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial, https://www.nejm.org/doi/full/10.1056/NEJMoa2022926.
Rentsch et al., The Lancet Rheumatology, doi:10.1016/S2665-9913(20)30378-7 (preprint 9/9, https://www.medrxiv.org/content/10.1101/2020.09.04.20187781v1), Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform, https://www.sciencedirect.com/science/article/pii/S2665991320303787.
Revollo et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkaa477, Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers, https://academic.oup.com/jac/advan..le/doi/10.1093/jac/dkaa477/5997449.
Rivera et al., Cancer Discovery, doi:10.1158/2159-8290.CD-20-0941, Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study, https://cancerdiscovery.aacrjourna..ly/2020/09/12/2159-8290.CD-20-0941.
Rivera-Izquierdo et al., Medicina Clínica, doi:10.1016/j.medcli.2020.06.025, Agentes terapéuticos utilizados en 238 pacientes hospitalizados por COVID-19 y su relación con la mortalidad, https://www.sciencedirect.com/science/article/pii/S0025775320304486.
Rodriguez-Gonzalez et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106249, COVID-19 in hospitalized patients in Spain: a cohort study in Madrid, https://www.sciencedirect.com/science/article/pii/S0924857920304696.
Roomi et al., J. Medical Internet Research, doi:10.2196/21758, Efficacy of hydroxychloroquine and tocilizumab in patients with COVID-19: A single-center retrospective chart review, https://www.jmir.org/2020/9/e21758/.
Rosenberg et al., JAMA, May 11, 2020, doi:10.1001/jama.2020.8630, Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State, https://jamanetwork.com/journals/jama/fullarticle/2766117.
Russian Government, ВРЕМЕННЫЕ МЕТОДИЧЕСКИЕ РЕКОМЕНДАЦИИ ПРОФИЛАКТИКА, ДИАГНОСТИКА И ЛЕЧЕНИЕ НОВОЙ КОРОНАВИРУСНОЙ ИНФЕКЦИИ (COVID-19), https://static-0.minzdrav.gov.ru/s..D0%9C%D0%A0_COVID-19_%28v.9%29.pdf.
Russian Government (B), Распоряжение Правительства Российской Федерации от 16.04.2020 № 1030-р, http://publication.pravo.gov.ru/Document/View/0001202004160037#print.
Salazar et al., The American Journal of Pathology, doi:10.1016/j.ajpath.2020.10.008, Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG, https://www.sciencedirect.com/science/article/pii/S0002944020304892.
Saleemi et al., medRxiv, doi:10.1101/2020.08.05.20151027, Time to negative PCR from symptom onset in COVID-19 patients on Hydroxychloroquine and Azithromycin - A real world experience, https://www.medrxiv.org/content/10.1101/2020.08.05.20151027v1.
Sánchez-Álvarez et al., Nefrología, doi:10.1016/j.nefroe.2020.04.002, Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN), https://www.sciencedirect.com/science/article/pii/S201325142030050X.
Sands et al., International Journal of Infectious Diseases, doi:/10.1016/j.ijid.2020.12.060, No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19, https://www.sciencedirect.com/science/article/pii/S1201971220325832.
Sarfaraz et al., medRxiv, doi:10.1101/2020.12.28.20248920, Determinants of in-hospital mortality in COVID-19; a prospective cohort study from Pakistan, https://www.medrxiv.org/content/10.1101/2020.12.28.20248920v1.
Sbidian et al., medRxiv, doi:10.1101/2020.06.16.20132597, Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France, https://www.medrxiv.org/content/10.1101/2020.06.16.20132597v1.
Self et al., JAMA, doi:10.1001/jama.2020.22240, Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial, https://jamanetwork.com/journals/jama/fullarticle/2772922.
Serrano et al., Ann. Oncol., 2020, Sep, 31, S1026, doi:10.1016/j.annonc.2020.08.1830, COVID-19 and lung cancer: What do we know?, https://www.annalsofoncology.org/a..cle/S0923-7534(20)41826-5/fulltext.
Shabrawishi et al., medRxix, doi:10.1101/2020.05.08.20095679, Negative nasopharyngeal SARS-CoV-2 PCR conversion in response to different therapeutic interventions, https://www.medrxiv.org/content/10.1101/2020.05.08.20095679v1.
Sheshah et al., Diabetes Research and Clinical Practice, doi:10.1016/j.diabres.2020.108538, Prevalence of Diabetes, Management and Outcomes among Covid-19 Adult Patients Admitted in a Specialized Tertiary Hospital in Riyadh, Saudi Arabia, https://www.sciencedirect.com/science/article/pii/S0168822720307956.
Shoaibi et al., medRxiv, doi:10.1101/2020.09.23.20199463, Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients, https://www.medrxiv.org/content/10.1101/2020.09.23.20199463v1.
Signes-Costa et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.11.012, Prevalence and 30-day mortality in hospitalized patients with COVID-19 and prior lung diseases, https://www.sciencedirect.com/science/article/pii/S0300289620305354.
Simova et al., New Microbes and New Infections, doi:10.1016/j.nmni.2020.100813, Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health care workers, https://www.sciencedirect.com/science/article/pii/S2052297520301657.
Simova (B) et al., New Microbes and New Infections, doi:10.1016/j.nmni.2020.100813, Hydroxychloroquine for prophylaxis and treatment of COVID-19 in health care workers, https://www.sciencedirect.com/science/article/pii/S2052297520301657.
Singer et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-218500, Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis, https://ard.bmj.com/content/early/2020/08/19/annrheumdis-2020-218500.
Singh et al., medRxiv, doi:10.1101/2020.05.12.20099028, Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the United States- Real-World Evidence From a Federated Electronic Medical Record Network, https://www.medrxiv.org/content/10.1101/2020.05.12.20099028v1.
Skipper et al., Annals of Internal Medicine, doi:10.7326/M20-4207, Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial, https://www.acpjournals.org/doi/10.7326/M20-4207.
Solh et al., medRxiv, doi:10.1101/2020.10.16.20214130, Clinical course and outcome of COVID-19 acute respiratory distress syndrome: data from a national repository, https://www.medrxiv.org/content/10.1101/2020.10.16.20214130v1.
SOLIDARITY Trial Consortium, NEJM, doi:10.1056/NEJMoa2023184 (preprint 10/15), Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results, https://www.nejm.org/doi/full/10.1056/NEJMoa2023184.
Sosa-García et al., Cir Cir. 2020, 88:5, 569-575, doi:10.24875/CIRU.20000675, Experience in the management of severe COVID-19 patients in an intensive care unit, https://cirugiaycirujanos.com/frame_esp.php?id=358.
Soto-Becerra et al., medRxiv, doi:10.1101/2020.10.06.20208066, Real-World Effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: Results of a target trial emulation using observational data from a nationwide Healthcare System in Peru, https://www.medrxiv.org/content/10.1101/2020.10.06.20208066v1.
Su et al., BioScience Trends, doi:10.5582/bst.2020.03340, Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China, https://www.jstage.jst.go.jp/artic..vpub_2020.03340/_article/-char/ja/.
Sulaiman et al., medRxiv, doi:10.1101/2020.09.09.20184143, The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in Ambulatory Care Settings: A Nationwide Prospective Cohort Study, https://www.medrxiv.org/content/10.1101/2020.09.09.20184143v1.
Sweeting et al., Statistics in Medicine, doi:10.1002/sim.1761, What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data, https://onlinelibrary.wiley.com/doi/10.1002/sim.1761.
Synolaki et al., medRxiv, doi:10.1101/2020.09.05.20184655, The Activin/Follistatin-axis is severely deregulated in COVID-19 and independently associated with in-hospital mortality, https://www.medrxiv.org/content/10.1101/2020.09.05.20184655v2.
Taccone et al., The Lancet Regional Health - Europe, doi:10.1016/j.lanepe.2020.100019, The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium, https://www.sciencedirect.com/science/article/pii/S2666776220300193.
Tan et al., Virus Research, doi:10.1016/j.virusres.2020.198262, A retrospective comparison of drugs against COVID-19, https://www.sciencedirect.com/scie../article/abs/pii/S0168170220311692.
Tang et al., BMJ 2020, 369, doi:10.1136/bmj.m1849, Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial, https://www.bmj.com/content/369/bmj.m1849.
Tehrani et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.10.071, Risk factors for mortality in adult COVID-19 patients; frailty predicts fatal outcome in older patients, https://www.sciencedirect.com/science/article/pii/S1201971220322761.
Teller Report, Coronavirus: a study in Senegal confirms the effectiveness of hydroxychloroquine, http://www.tellerreport.com/news/2..hydroxychloroquine.BJeet4Kst8.html.
Texeira et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa439.560, Characteristics and outcomes of COVID-19 patients admitted to a regional health system in the southeast, https://academic.oup.com/ofid/article/7/Supplement_1/S251/6058327.
The Africa Report, Coronavirus: Didier Raoult the African and chloroquine, from Dakar to Brazzaville, https://www.theafricareport.com/26..roquine-from-dakar-to-brazzaville/.
The Australian, India and Indonesia stand by antimalarials, https://www.theaustralian.com.au/w..y/d7856d1371697fe69e4fcc39d7f1f97c.
The BL, Russia supports the use of hydroxychloroquine, the drug to treat the CCP Virus suggested by Trump, https://thebl.com/world-news/russi..oroquine-drug-ccp-virus-trump.html.
The East African, Algeria backs use of malaria drug despite WHO dropping trials, https://www.theeastafrican.co.ke/n../4552902-5564930-duphp6/index.html.
The Guardian, Chloroquine potent for COVID-19 prevention, says NAFDAC, https://guardian.ng/news/nigeria/n..r-covid-19-prevention-says-nafdac/.
The Indian Express, Vadodara administration drive: HCQ helping in containing Covid-19 cases, say docs as analysis begins, https://indianexpress.com/article/..y-docs-as-analysis-begins-6486049/.
The Moscow Times, Russia Approves Unproven Malaria Drug to Treat Coronavirus, https://www.themoscowtimes.com/202..a-drug-to-treat-coronavirus-a70025.
The New York Times, Malaria Drug Taken by Trump Is Tied to Increased Risk of Heart Problems and Death in New Study, https://www.nytimes.com/2020/05/22..alaria-drug-trump-coronavirus.html.
The New York Times (B), Small Chloroquine Study Halted Over Risk of Fatal Heart Complications, https://www.nytimes.com/2020/04/12..ronavirus-trump.html?smid=em-share.
The New York Times (C), Malaria Drug Promoted by Trump Did Not Prevent Covid Infections, Study Finds, https://www.nytimes.com/2020/06/03..chloroquine-coronavirus-trump.html.
The New York Times (D), Coronavirus Can Be Deadly for Young Adults, Too, Study Finds, https://www.nytimes.com/2020/09/10/world/covid-19-coronavirus.html.
The North Africa Post, Morocco continues use of Chloroquine despite controversy, https://northafricapost.com/41247-..loroquine-despite-controversy.html.
The Tico Times, News briefs: Reopening plans on-track, hydroxychloroquine use to continue, partnership with Coursera, https://ticotimes.net/2020/06/15/n..continue-partnership-with-coursera.
Treanor et al., JAMA, 2000, 283:8, 1016-1024, doi:10.1001/jama.283.8.1016, Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial, https://jamanetwork.com/journals/jama/fullarticle/192425.
Trefond et al., SSRM, doi:10.2139/ssrn.3754815, Impact of hydroxychloroquine used as DMARD on SARS CoV-2 tests and COVID-19 evolution, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3754815.
Trullàs et al., Research Square, doi:10.21203/rs.3.rs-39421/v1 , High in-hospital mortality due to COVID-19 in a community hospital in Spain: a prospective observational study, https://www.researchsquare.com/article/rs-39421/v1.
Ukrinform, Ukraine receives batch of hydroxychloroquine tablets from India, https://www.ukrinform.net/rubric-e..ose-down-in-ukraine-on-june-3.html.
Ulrich et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa446, Treating Covid-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind, Randomized Controlled Trial in Hospitalized Patients, https://academic.oup.com/ofid/adva..e/doi/10.1093/ofid/ofaa446/5910201.
United States National Institutes of Health, Chloroquine or Hydroxychloroquine With or Without Azithromycin, https://www.covid19treatmentguidel..uine-with-or-without-azithromycin/.
van Halem et al., BMC Infect Dis., doi:10.1186/s12879-020-05605-3, Risk factors for mortality in hospitalized patients with COVID-19 at the start of the pandemic in Belgium: a retrospective cohort study, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691970/.
Vanguard, COVID-19: Nigerian study finds Chloroquine, Hydroxychloroquine effective as Prophylaxis, https://www.vanguardngr.com/2020/0..oroquine-effective-as-prophylaxis/.
Vernaz et al., Swiss Medical Weekly, doi:10.4414/smw.2020.20446 , Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs, https://smw.ch/article/doi/smw.2020.20446.
Voice of America, Cameroon Begins Large-scale Chloroquine Production, https://www.voanews.com/science-he..large-scale-chloroquine-production.
Wang et al., medRxiv, doi:10.1101/2020.06.11.20128926, Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System, https://www.medrxiv.org/content/10.1101/2020.06.11.20128926v1.
Xia et al., ChiCTR2000029741, Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study, http://www.chictr.org.cn/showproj.aspx?proj=49263.
Yegerov et al., medRxiv, doi:10.1101/2021.01.06.20249091, Epidemiological and Clinical Characteristics, and Virologic Features of COVID-19 Patients in Kazakhstan: a Nation-Wide, Retrospective, Cohort Study, https://www.medrxiv.org/content/10.1101/2021.01.06.20249091v1.
Yu et al., Science China Life Sciences, 2020 Aug 3, doi:10.1007/s11427-020-1782-1, Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs, https://link.springer.com/article/10.1007/s11427-020-1782-1.
Yu (B) et al., Science China Life Sciences, 2020 Aug 3, doi:10.1007/s11427-020-1782-1, Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs, https://link.springer.com/article/10.1007/s11427-020-1782-1.
Yu (C) et al., Science China Life Sciences, 2020 May 15, 1-7, doi:10.1007/s11427-020-1732-2, Low Dose of Hydroxychloroquine Reduces Fatality of Critically Ill Patients With COVID-19, https://link.springer.com/article/10.1007%2Fs11427-020-1732-2.
Zhang et al., JAMA, 80:19, 1690, doi:10.1001/jama.280.19.1690, What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes, https://jamanetwork.com/journals/jama/fullarticle/188182.
290.
Zhong Nanshan (钟南山), Efficacy and safety of chloroquine for treatment of COVID-19. An open-label, multi-center, non-randomized trial, https://twitter.com/JamesTodaroMD/status/1243260720944480265.291. Zhong (B) et al., Lancent Rheumatology, 10.1016/S2665-9913(20)30227-7, COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study, https://www.thelancet.com/journals../PIIS2665-9913(20)30227-7/fulltext.
Comments
Post a Comment